How to buy Immutep shares | A$0.25
Own Immutep shares in just a few minutes.
We’re committed to our readers and editorial independence. We don’t compare all products in the market and may receive compensation when we refer you to our partners, but this does not influence our opinions or reviews. Learn more about Finder .
Immutep Limited is a biotechnology business based in Australia. Immutep shares (IMM) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.25 – an increase of 2.04% over the previous week. Immutep has a trailing 12-month revenue of around $13.7 million.
How to buy shares in Immutep
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Immutep . Find the share by name or ticker symbol: IMM. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immutep reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $0.25, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Immutep . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
🧪How we chose these brokersFor our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.
How has coronavirus impacted Immutep 's share price?
Since the stock market crash in March caused by coronavirus, Immutep 's share price has had significant negative movement.
Its last market close was $0.25, which is 39.76% down on its pre-crash value of $0.415 and 150.00% up on the lowest point reached during the March crash when the shares fell as low as $0.1.
If you had bought $1,000 worth of Immutep shares at the start of February 2020, those shares would have been worth $876.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $769.23.
Immutep share priceUse our graph to track the performance of IMM stocks over time.
Immutep shares at a glance
|Latest market close||AUDA$0.25|
|52-week range||AUDA$0.1 - AUDA$0.445|
|50-day moving average||AUDA$0.2302|
|200-day moving average||AUDA$0.1829|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.006|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Immutep stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Immutep price performance over time
|1 week (2020-10-15)||2.04%|
|1 month (2020-09-23)||-1.96%|
|3 months (2020-07-22)||25.00%|
|6 months (2020-04-22)||56.25%|
|1 year (2019-10-22)||-7.41%|
|2 years (2018-10-22)||-45.28%|
|3 years (2017-10-20)||-13.19%|
|5 years (2015-10-22)||-56.60%|
|Revenue TTM||$13.7 million|
|Gross profit TTM||$-6,656,699|
|Return on assets TTM||-21.62%|
|Return on equity TTM||-46.69%|
|Market capitalisation||$120.8 million|
TTM: trailing 12 months
Immutep share dividends
We're not expecting Immutep to pay a dividend over the next 12 months.
Have Immutep 's shares ever split?
Immutep 's shares were split on a 1:10 basis on 4 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep 's share price.
Immutep share price volatility
Over the last 12 months, Immutep 's shares have ranged in value from as little as $0.1 up to $0.445. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Immutep 's is 1.343. This would suggest that Immutep 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Frequently asked questions
More guides on Finder
Where to buy Xbox One racing wheels online in Australia
A list of stores to buy Xbox One racing wheels online in Australia.
Where to buy Xbox One consoles online in Australia
A list of stores to buy Xbox One consoles online in Australia.
Where to buy Xbox One chargers online in Australia
A list of stores to buy Xbox One chargers online in Australia.
Where to buy Xbox One cables online in Australia
A list of stores to buy Xbox One cables online in Australia.
Where to buy Xbox 360 online in Australia
A list of stores to buy Xbox 360 online in Australia.
Where to buy Xbox 360 remotes online in Australia
A list of stores to buy Xbox 360 remotes online in Australia.
Where to buy Xbox 360 racing wheels online in Australia
A list of stores to buy Xbox 360 racing wheels online in Australia.
Where to buy Xbox 360 headsets online in Australia
A list of stores to buy Xbox 360 headsets online in Australia.
Where to buy Xbox 360 games online in Australia
A list of stores to buy Xbox 360 games online in Australia.
Where to buy Xbox 360 gamepads & standard controllers online in Australia
A list of stores to buy Xbox 360 gamepads & standard controllers online in Australia.
Ask an Expert